<img src="https://ws.zoominfo.com/pixel/eCRg8hzy2qp0kNUl6E1g" width="1" height="1" style="display: none;">

Newsroom

Press Releases

Our latest announcements

Biodesix to Present at World CDx

Paul Beresford, Ph.D., will present at the 2013 World CDx Summit taking place in Boston, November 12-15, 2013; Benefits of proteomics in test discovery.

Biodesix® Announces Additional Data in Phase III Lung Cancer Diagnostic Study

PROSE confirms VeriStrat can predict differential treatment outcomes in 2nd line advanced NCLSC patients.

Biodesix Secures Medicare Coverage for VeriStrat Test

Bioesix's Veristrat test gains coverage from Medicare. More than 49 million Medicare enrollees in the U.S. will now be able to benefit from VeriStrat.

Biodesix Announces Results in Phase III Lung Cancer Diagnostic Study; First Prospective Biomarker-Stratified Validation Study in Oncology

Data confirms that the blood-based protein diagnostic is predictive of differential treatment outcomes between two types of therapies for 2nd line NSCLC.

Biodesix to Announce Results of VeriStrat® Biomarker Study

Biodesix presents data on VeriStrat biomarker study at ASCO 2013

Biodesix Closes Series D Financing

Biodesix closed on $8.8 million in a follow-on sale of its Series D preferred shares.

Peer-Reviewed Study Confirms VeriStrat® Test from Biodesix Provides Useful Information for Physicians in Managing Patients with Lung Cancer

Study demonstrates that physicians are using the company’s VeriStrat test to help guide treatment decisions for patients with NSCLC.

Biodesix’ Heinrich Roder Presents at 2013 Biomarker Summit

Dr. Roder will discuss the use of Biodesix’ high throughput mass spectrometry technology, Deep MALDI, to generate protein signatures for Oncology questions.

VeriStrat® Provides Oncologists with More Information to Personalize Therapy for Elderly Patients With Lung Cancer

Journal of Thoracic Oncology Study: VerStrat provides oncologists with more information to personalize therapy for their patients.

VeriStrat® Test Predicts Differential Treatment Benefit between Chemotherapy and Targeted Therapy for Lung Cancer Patients

Analysis showed that the VeriStrat test was able to identify patients more likely to have a slower progression of disease with select treatments.